These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 9291738)

  • 41. A fast and robust dual-label nonradioactive oligonucleotide ligation assay for detection of factor V Leiden.
    Chakravarty A; Hansen TS; Hørder M; Kristensen SR
    Thromb Haemost; 1997 Oct; 78(4):1234-6. PubMed ID: 9364990
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Functional activated protein C resistance assays: correlation with factor V DNA analysis is better with RVVT-than APTT-based assays.
    Favaloro EJ; Mirochnik O; McDonald D
    Br J Biomed Sci; 1999; 56(1):23-33. PubMed ID: 10492912
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Clinical findings in individuals with the factor V Leiden mutation].
    Matýsková M; Vorlová Z; Hrachovinová I; Buliková A; Zavrelová J; Slechtová M
    Vnitr Lek; 1997 May; 43(5):298-301. PubMed ID: 9601852
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Factor V Leiden mutation: an unrecognized cause of hemiplegic cerebral palsy, neonatal stroke, and placental thrombosis.
    Thorarensen O; Ryan S; Hunter J; Younkin DP
    Ann Neurol; 1997 Sep; 42(3):372-5. PubMed ID: 9307261
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical relevance of inherited thrombophilia in implantation failure: who needs to be screened?
    Grandone E; Colaizzo D; Lo Bue A; Cappucci F; Cittadini E; Margaglione M
    Haematologica; 2003 Dec; 88(12):ELT35. PubMed ID: 14688014
    [No Abstract]   [Full Text] [Related]  

  • 46. [Activated protein C resistance in factor V disease: how high is the risk of thrombosis?].
    Spannagl M; Schramm W
    Dtsch Med Wochenschr; 1998 Feb; 123(6):137-9. PubMed ID: 9505951
    [No Abstract]   [Full Text] [Related]  

  • 47. Incidence of venous thromboembolism in families with inherited thrombophilia.
    Simioni P; Sanson BJ; Prandoni P; Tormene D; Friederich PW; Girolami B; Gavasso S; Huisman MV; Büller HR; Wouter ten Cate J; Girolami A; Prins MH
    Thromb Haemost; 1999 Feb; 81(2):198-202. PubMed ID: 10063991
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cardiology patient page. Factor V Leiden.
    Ornstein DL; Cushman M
    Circulation; 2003 Apr; 107(15):e94-7. PubMed ID: 12707252
    [No Abstract]   [Full Text] [Related]  

  • 49. [Activated protein C resistance and mutation of coagulation factor V].
    Samama MM
    Arch Mal Coeur Vaiss; 1996 Jun; 89(6):669-70. PubMed ID: 8760650
    [No Abstract]   [Full Text] [Related]  

  • 50. Multiplex PCR for one-step determination of the G20210A variation and the factor V Leiden mutation by denaturing gradient gel electrophoresis (DGGE).
    Patri S; Salmeron S; Caillon M; Kitzis A; Chomel JC
    Thromb Haemost; 1999 Feb; 81(2):313-4. PubMed ID: 10064013
    [No Abstract]   [Full Text] [Related]  

  • 51. [Acquired resistance to activated protein C in pregnancy].
    Schneider DM; von Tempelhoff GF; Hoppenstaedt D; Fareed J; Heilmann L
    Z Geburtshilfe Neonatol; 1998; 202(3):107-10. PubMed ID: 9715525
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Association between inherited thrombophilias, antiphospholipid antibodies, and lipoprotein A levels and venous thromboembolism in pregnancy.
    Ogunyemi D; Cuellar F; Ku W; Arkel Y
    Am J Perinatol; 2003 Jan; 20(1):17-24. PubMed ID: 12638077
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Activated protein C resistance and lupus anticoagulant activity induced by plasma and purified monospecific human IgG anti-beta2-glycoprotein-I antibodies.
    Viveros ME; Cabiedes J; Reyes E; Cabral AR
    Rev Invest Clin; 2005; 57(4):563-71. PubMed ID: 16315641
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Measurement of activated protein C resistance during menstrual cycle in women with and without the Leiden mutation.
    Wramsby ML; Bremme K; Blombäck M
    Thromb Haemost; 2001 Apr; 85(4):614-8. PubMed ID: 11341494
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Factor V Leiden (R506Q) and risk of venous thromboembolism: a case-control study based on the Spanish population.
    García-Gala JM; Alvarez V; Pinto CR; Soto I; Urgellés MF; Menéndez MJ; Carracedo C; López-Larrea C; Coto E
    Clin Genet; 1997 Oct; 52(4):206-10. PubMed ID: 9383024
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Family secrets to be disclosed.
    Lindqvist PG; Carlson J
    J Thromb Haemost; 2006 Oct; 4(10):2180-1. PubMed ID: 16881960
    [No Abstract]   [Full Text] [Related]  

  • 57. Phenprocoumon-induced hepatitis delaying precise diagnosis in a thrombophilic patient with activated protein C resistance due to factor V R506Q mutation.
    Wuillemin WA; Zenhäusern R; Bernhard MC; Lämmle B
    Am J Med; 1997 Nov; 103(5):437-9. PubMed ID: 9375713
    [No Abstract]   [Full Text] [Related]  

  • 58. Laboratory diagnosis of resistance to activated protein C (APC-resistance).
    Bertina RM
    Thromb Haemost; 1997 Jul; 78(1):478-82. PubMed ID: 9198200
    [No Abstract]   [Full Text] [Related]  

  • 59. Factor V Leiden and thrombophilia.
    Simioni P; Scudeller A; Girolami A
    N Engl J Med; 1995 May; 332(20):1382. PubMed ID: 7715653
    [No Abstract]   [Full Text] [Related]  

  • 60. Molecular genetics of thrombophilia: factor V gene mutation causing resistance to activated protein C as a basis of the hypercoagulable state.
    Dahlbäck B
    J Lab Clin Med; 1995 May; 125(5):566-71. PubMed ID: 7738422
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.